Mus­tang inks a deal for in vi­vo CAR-T tech from the Mayo Clin­ic; How a spilled cup of tea land­ed one biotech $11.7 mil­lion

As part of its push to de­vel­op an off-the-shelf CAR-T ther­a­py, Mus­tang Bio has inked a deal for new tech­nol­o­gy out of the Mayo Clin­ic de­signed to form CAR-T cells in­side the pa­tient.

The two-step ap­proach comes from the lab of Lar­ry Pease, prin­ci­pal in­ves­ti­ga­tor and for­mer di­rec­tor of the Mayo Clin­ic’s Cen­ter for Im­munol­o­gy and Im­mune Ther­a­pies. First, the pa­tient re­ceives a pep­tide that dri­ves the rapid re­pro­duc­tion of the body’s own res­i­dent T cells. Then, a vi­ral CAR con­struct is ad­min­is­tered di­rect­ly in­to the pa­tient’s lymph nodes. That con­struct in­fects the ac­ti­vat­ed T cells, and es­sen­tial­ly forms CAR-T cells in vi­vo. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.